SPRUCE BIOSCIENCES NOW ENROLLING TRIALS FOR ADULT PATIENTS LIVING WITH CLASSIC CAH
Clinical management of classic CAH is a balance between reducing excessive doses of glucocorticoids and reducing adrenal androgen levels. Investigational drug tildacerfont (once-daily treatment) from Spruce Biosciences has the potential to reduce androgen levels and address CAH symptom control such that steroid dosing could be reduced.
Click here to learn more details about the studies.
Visit the trial website to see if you qualify to enroll in the studies: www.CAHstudy.com.
Click here to learn more details about the studies.
Visit the trial website to see if you qualify to enroll in the studies: www.CAHstudy.com.